RECURSION PHARMACEUTICALS-A (RXRX) Forecast, Price Target & Analyst Ratings

NASDAQ:RXRX • US75629V1044

Current stock price

3.78 USD
+0.18 (+5%)
At close:
3.78 USD
0 (0%)
After Hours:

Analyst forecast overview

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for RECURSION PHARMACEUTICALS-A (RXRX).

Forecast Snapshot

Consensus Price Target

Price Target
$6.85
+ 81.18% Upside
→ Price target details

Next Earnings Forecast

Earnings Estimate
Release Date
May 11, 2026
Period
Q1 / 2026
EPS Estimate
-$0.28
Revenue Estimate
17.809M
→ Full earnings forecast details

ChartMill Buy Consensus

Rating
74.29%
Weighted Analyst Rating Score
→ Analyst Ratings details

Price Target Details & History

Consensus Price Target and Range

Mean target
$6.85
Upside
+ 81.18%
From current price of $3.78 to mean target of $6.85, Based on 14 analyst forecasts
Low
$3.03
Median
$6.12
High
$11.55

Price Target Revisions

1 Month
-4.08%
3 Months
-4.08%

Price Target Summary

14 Wall Street analysts provided a forecast for the next 12 months for RXRX. The average price target is 6.85 USD. This implies a price increase of 81.18% is expected in the next year compared to the current price of 3.78.
The average price target has been revised downward by 4.08% in the past 3 months.
→ Find peer stocks trading 30% below analyst price target

Analyst Ratings & History

Current Analyst Ratings

RXRX Current Analyst RatingRXRX Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 1 2 3 4 5

Analyst Ratings History

RXRX Historical Analyst RatingsRXRX Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -19 -17 -15 -13 -11 -9 -7 -5 -3 -1 2 4 6 8 10

Analyst Ratings Consensus

ChartMill Buy Consensus
74.29%
RXRX was analyzed by 14 analysts. The buy percentage consensus is at 74. So analysts seem to be have mildly positive about RXRX.
In the previous month the buy percentage consensus was at a similar level.
RXRX was analyzed by 14 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
→ Find peer stocks with a buy consensus above 85%

Recent Upgrades & Downgrades

DateFirmActionFrom → To
2026-02-26NeedhamReiterate Buy -> Buy
2026-02-26B of A SecuritiesMaintains Neutral -> Neutral
2025-12-17JP MorganUpgrade Neutral -> Overweight
2025-09-11NeedhamReiterate Buy -> Buy
2025-07-08NeedhamReiterate Buy -> Buy
2025-06-16Morgan StanleyMaintains Equal-Weight -> Equal-Weight
2025-05-06NeedhamMaintains Buy -> Buy
2025-04-10Morgan StanleyMaintains Equal-Weight -> Equal-Weight
2025-04-08NeedhamReiterate Buy -> Buy
2025-02-28Leerink PartnersMaintains Market Perform -> Market Perform
2025-02-06NeedhamReiterate Buy -> Buy
2025-01-08KeybancMaintains Overweight -> Overweight
2024-12-11NeedhamReiterate Buy -> Buy
2024-11-20NeedhamReiterate Buy -> Buy
2024-11-07NeedhamReiterate Buy -> Buy
2024-09-04NeedhamMaintains Buy -> Buy
2024-09-03Leerink PartnersMaintains Market Perform -> Market Perform
2024-09-03JefferiesMaintains Hold -> Hold
2024-08-09NeedhamMaintains Buy -> Buy
2024-07-11KeybancMaintains Overweight -> Overweight
2024-06-25NeedhamReiterate Buy -> Buy
2024-05-10NeedhamReiterate Buy -> Buy
2024-04-09NeedhamReiterate Buy -> Buy
2024-03-04KeybancMaintains Overweight -> Overweight
2024-02-28NeedhamMaintains Buy -> Buy

Next Earnings Forecast Details

Next Earnings Details

Release Date
May 11, 2026
Period
Q1 / 2026
EPS Estimate
-$0.28
Revenue Estimate
17.809M
Revenue Q2Q
20.78%
EPS Q2Q
44.04%
Number of Analysts
10

Next Earnings Revisions

Revenue (1 Month)
0.00%
Revenue (3 Months)
7.24%
EPS (1 Month)
0.00%
EPS (3 Months)
21.18%

Next Earnings Summary

RXRX is expected to report earnings on 5/11/2026. The consensus EPS estimate for the next earnings is -0.28 USD and the consensus revenue estimate is 17.81M USD.
The next earnings revenue estimate has been revised upward by 7.24% in the past 3 months. Upward revisions are a positive sign and indicate that analysts are more optimistic about the next earnings compared to 3 months ago.
→ Find peers expecting at least 20% revenue growth next quarter

Full Analyst Estimates 2026 - 2032

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

2023 2024 2025 2026 2027 2028 2029 2030 2031 2032
Revenue
YoY % growth
RXRX revenue by date.RXRX revenue by date.
44.575M
11.89%		58.839M
32.00%		74.681M
26.92%		83.726M
12.11%		152.82M
82.52%		151.42M
-0.92%		252.45M
66.72%		370.87M
46.91%		529.69M
42.82%		774.18M
46.16%
EBITDA
YoY % growth
RXRX ebitda by date.RXRX ebitda by date.
-324.458M
-38.68%		-442.51M
-36.38%		-564.431M
-27.55%		-482.581M
14.50%		-453.267M
6.07%		-229.005M
49.48%		N/AN/AN/AN/A
EBIT
YoY % growth
RXRX ebit by date.RXRX ebit by date.
-348.86M
-41.97%		-479.004M
-37.31%		-648.132M
-35.31%		-537.542M
17.06%		-291.613M
45.75%		-84.164M
71.14%		-605.37M
-619.28%		-561.612M
7.23%		-503.472M
10.35%		-397.188M
21.11%
Operating Margin
RXRX operating margin by date.RXRX operating margin by date.
-782.64%-814.09%-867.87%-642.03%-190.82%-55.58%-239.80%-151.43%-95.05%-51.30%
EPS
YoY % growth
RXRX eps by date.RXRX eps by date.
-1.57
-14.60%		-1.66
-5.73%		-1.48
10.84%		-1.03
30.49%		-0.89
13.88%		-0.67
24.40%		-0.96
-43.15%		-0.81
15.96%		-0.66
17.72%		-0.48
27.69%

All data in USD

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

Q1 / 26 Q2 / 26 Q3 / 26 Q4 / 26 Q1 / 27 Q2 / 27 Q3 / 27 Q4 / 27
EPS
Q2Q % growth		-0.28
44.04%		-0.27
34.61%		-0.26
26.74%		-0.26
-23.51%		-0.25
10.68%		-0.24
10.60%		-0.23
12.98%		-0.20
21.35%
Revenue
Q2Q % growth		17.809M
20.78%		17.806M
-7.37%		21.784M
320.95%		27.843M
-21.65%		24.48M
37.46%		23.205M
30.32%		24.633M
13.08%		52.632M
89.03%
EBITDA
Q2Q % growth		-123.96M
27.95%		-120.33M
9.56%		-121.681M
-12.69%		-132.605M
-438.32%		N/AN/AN/AN/A
EBIT
Q2Q % growth		-135.608M
29.14%		-132.606M
24.75%		-129.711M
24.67%		-138.921M
-28.23%		-107.151M
20.98%		-106.131M
19.97%		-106.233M
18.10%		-128.673M
7.38%

All data in USD

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

RXRX Yearly Revenue VS EstimatesRXRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M
RXRX Yearly EPS VS EstimatesRXRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 -0.5 -1 -1.5

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year
15.67%
EPS Next 5 Year
7.80%

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year
34.09%
Revenue Next 5 Year
42.64%

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year
18.72%
EBIT Next 5 Year
N/A
→ Find peers expecting at least 20% CAGR revenue growth over the next 3 years

RECURSION PHARMACEUTICALS-A / RXRX Forecast FAQ

What is the average price target for RECURSION PHARMACEUTICALS-A (RXRX) stock?

14 analysts have analysed RXRX and the average price target is 6.85 USD. This implies a price increase of 81.18% is expected in the next year compared to the current price of 3.78.

What is the next earnings date for RXRX stock?

RECURSION PHARMACEUTICALS-A (RXRX) will report earnings on 2026-05-11.

What are the consensus estimates for RXRX stock next earnings?

The consensus EPS estimate for the next earnings of RECURSION PHARMACEUTICALS-A (RXRX) is -0.28 USD and the consensus revenue estimate is 17.81M USD.

What is the number of analysts for RXRX stock?

The number of analysts covering RECURSION PHARMACEUTICALS-A (RXRX) is 14.